Table 2.
Treatment and Results
| Patient | Age, y | Treatment Arm | Response | Remission Time, Weeks | Recurrence | Survival, Weeks | Status |
|---|---|---|---|---|---|---|---|
| 1 | 48 | VAD | CR | 35 | Yes | 48 | Dead |
| 2 | 24 | VAD | CR | ≥547 | No | ≥550 | Alive |
| 3 | 78 | HCVAD | CR | 8 | No | 12 | Dead (CR) |
| 4 | 33 | HCVAD | CR | ≥623 | No | ≥625 | Alive |
| 5 | 59 | HCVAD | CR | 40 | Yes | 106 | Dead |
| 6 | 21 | HCVAD | CR | ≥404 | No | ≥407 | Alive |
| 7 | 28 | HCVAD | CR | ≥352 | No | ≥355 | Alive |
| 8 | 18 | HCVAD | CR | ≥308 | No | ≥312 | Alive |
| 9 | 28 | HCVAD | CR | ≥219 | No | ≥222 | Alive |
| 10 | 17 | HCVAD+rituximab | CR | ≥160 | No | ≥163 | Alive |
| 11 | 41 | HCVAD | CR | ≥117 | No | ≥120 | Alive |
| 12 | 39 | HCVAD | CR | ≥4 | No | ≥7 | Alive |
VAD indicates combined vincristine, doxorubicin (Adriamycin), and decadron; HCVAD, fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine; CR, complete remission.